Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer
To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Carcinoma, Non-Small-Cell Lung
DRUG: PF-3512676 + Erlotinib|DRUG: Erlotinib
Progression-Free Survival, 50Events
Overall Safety Profile, 28 days post treatment|Time to Tumor Progression, End of treatment|Overall Objective Response Rate, Time of disease progression|Duration of Response, Time of disease progression|Overall Survival, Time of death
To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemotherapy regimen.